Literature DB >> 22366437

Prognostic utility of angiogenesis and hypoxia effectors in patients with operable squamous cell cancer of the larynx.

G Pentheroudakis1, I Nicolaou, V Kotoula, E Fountzilas, K Markou, A G Eleftheraki, A Fragkoulidi, I Karasmanis, A Tsigka, N Angouridakis, K Vlachtsis, A Nikolaou, N Pavlidis, G Fountzilas.   

Abstract

Angiogenesis is active in localised laryngeal squamous cell carcinoma. We assessed relative messenger RNA (mRNA) and immunohistochemical (IHC) expression of Vascular Endothelial Growth Factors (VEGF) A, B, C, their receptors VEGFR1, 2, 3, Neuropilins 1, 2 (NRP1, 2) and Hypoxia-Inducible Factor 1A (HIF1A) in paraffin-embedded localised laryngeal carcinomas. In 289 patients with T3-4 (77.8%), node-negative (84.1%) tumours of the larynx, high VEGFA and VEGFR1 mRNA correlated with advanced T stage, while low VEGFB and VEGFC mRNA with alcohol abuse and supraglottic primary, respectively (p<0.05). Age <55 was associated with high IHC expression of VEGFA, C and poor tumour differentiation with high IHC VEGFA. At a median follow-up of 74.5months, patients with VEGFR1-high tumours had significantly poorer disease-free survival (Hazard Ratio [HR] 1.93, p=0.008) and shorter overall survival (OS, HR 1.71, p=0.041). An association with dismal OS was seen for high VEGFR3 tumoural mRNA expression (HR 1.76, p=0.02). IHC expression of VEGF family proteins in the tumour was not prognostic and had poor concordance with mRNA expression (kappa<0.1, p=NS). In multivariate analysis, node-positive status, non-supraglottic localization, high VEGFR1 mRNA and high IHC VEGFA expression were significantly associated with relapse, while node-positive status, high VEGFR1 and VEGFC mRNA expression in the tumour with risk of death. In laryngeal cancer, upregulated mRNA expression of VEGFR1 and VEGFC is associated with poor patient outcome.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22366437     DOI: 10.1016/j.oraloncology.2012.02.002

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  5 in total

1.  VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy.

Authors:  Maria Christina Tsourlakis; Puya Khosrawi; Philipp Weigand; Martina Kluth; Claudia Hube-Magg; Sarah Minner; Christina Koop; Markus Graefen; Hans Heinzer; Corinna Wittmer; Guido Sauter; Till Krech; Waldemar Wilczak; Hartwig Huland; Ronald Simon; Thorsten Schlomm; Stefan Steurer
Journal:  Int J Mol Sci       Date:  2015-04-16       Impact factor: 5.923

2.  Identification and validation of a multigene predictor of recurrence in primary laryngeal cancer.

Authors:  Elena Fountzilas; Vassiliki Kotoula; Nikolaos Angouridakis; Ilias Karasmanis; Ralph M Wirtz; Anastasia G Eleftheraki; Elke Veltrup; Konstantinos Markou; Angelos Nikolaou; Dimitrios Pectasides; George Fountzilas
Journal:  PLoS One       Date:  2013-08-09       Impact factor: 3.240

3.  Aberrations in Angiogenic Signaling and MYC Amplifications are Distinguishing Features of Angiosarcoma.

Authors:  Vittal Kurisetty; Brad A Bryan
Journal:  Angiol Open Access       Date:  2013-04-08

4.  Insulin-like growth factor 1 receptor (IGF1R) expression and survival in operable squamous-cell laryngeal cancer.

Authors:  Giannis Mountzios; Ioannis Kostopoulos; Vassiliki Kotoula; Ioanna Sfakianaki; Elena Fountzilas; Konstantinos Markou; Ilias Karasmanis; Sofia Leva; Nikolaos Angouridakis; Konstantinos Vlachtsis; Angelos Nikolaou; Ioannis Konstantinidis; George Fountzilas
Journal:  PLoS One       Date:  2013-01-24       Impact factor: 3.240

5.  Brush cytology with immunocytochemical evaluation of VEGF expression versus biopsy in clinically precancerous laryngeal lesions: can we diagnose laryngeal cancer only with brush cytology?

Authors:  Angelos Chatziavramidis; Zinovia Tsinaslanidou; Rozalia Valeri; Iordanis Konstantinidis; Jannis Constantinidis
Journal:  Anal Cell Pathol (Amst)       Date:  2015-09-17       Impact factor: 2.916

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.